Citations (218)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (57)
Taru Hallinen, Santtu Kivelä, Erkki Soini, Veli-Pekka Harjola & Mari Pesonen. (2023) Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland. ClinicoEconomics and Outcomes Research 15, pages 1-13.
Read now
Read now
Jean-François Yale, Beatrice Osumili, Beth D. Mitchell, Barnaby Hunt, Gurjeev Sohi, Mark Jeddi, Donna Mojdami & William J. Valentine. (2022) Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis. Journal of Medical Economics 25:1, pages 238-248.
Read now
Read now
Pieralessandro Lasalvia, Yaneth Gil-Rojas & Ángel García. (2022) Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research 22:6, pages 955-964.
Read now
Read now
Yaneth Gil-Rojas, Pieralessandro Lasalvia & Ángel García. (2022) Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 655-663.
Read now
Read now
Stephane Roze, John J Isitt, Jayne Smith-Palmer & Peter Lynch. (2021) Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. ClinicoEconomics and Outcomes Research 13, pages 717-725.
Read now
Read now
Stéphane Roze, Maria Ida Buompensiere, Zeynep Ozdemir, Simona de Portu & Ohad Cohen. (2021) Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK. Journal of Medical Economics 24:1, pages 883-890.
Read now
Read now
Craig J. Currie. (2020) Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin. Postgraduate Medicine 132:8, pages 667-675.
Read now
Read now
Johan Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard, João da Rocha Fernandes, Ann-Charlotte Mårdby, Barnaby Hunt, Samuel J. P. Malkin & Maria Thunander. (2020) Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. Journal of Medical Economics 23:11, pages 1311-1320.
Read now
Read now
Ching-Lun Chien, Yen-Chou Chen, Daniel C. Malone, Yueh-Lung Peng & Yu Ko. (2020) Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Current Medical Research and Opinion 36:10, pages 1619-1626.
Read now
Read now
Johannes Pöhlmann, Roberta Montagnoli, Giusi Lastoria, Witesh Parekh, Marie Markert & Barnaby Hunt. (2019) Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy. ClinicoEconomics and Outcomes Research 11, pages 605-614.
Read now
Read now
Stephané Roze, Jayne Smith-Palmer, Simona de Portu, Alexis Delbaere, Bonnie de Brouwer & Harold W de Valk. (2019) Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. ClinicoEconomics and Outcomes Research 11, pages 73-82.
Read now
Read now
Xiaoling Cai, Lizheng Shi, Wenjia Yang, Shuyan Gu, Yingyao Chen, Lin Nie & Linong Ji. (2019) Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Journal of Medical Economics 22:4, pages 336-343.
Read now
Read now
Richard F Pollock, Barrie Chubb, William J Valentine & Simon Heller. (2018) Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. Diabetes, Metabolic Syndrome and Obesity 11, pages 217-226.
Read now
Read now
Michael Dempsey, Michelle Mocarski, Jakob Langer & Barnaby Hunt. (2018) Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of Medical Economics 21:11, pages 1110-1118.
Read now
Read now
Edurne Lecumberri, Maite Ortega, Marta Iturregui, José Antonio Quesada, Clotilde Vázquez & Domingo Orozco. (2018) Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec. Current Medical Research and Opinion 34:6, pages 1053-1059.
Read now
Read now
Abhiroop Chakravarty, Mohini Rastogi, Praveen Dhankhar & Kelly F. Bell. (2018) Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Journal of Medical Economics 21:5, pages 497-509.
Read now
Read now
Shraddha Chaugule & Claudia Graham. (2017) Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective. Journal of Medical Economics 20:11, pages 1128-1135.
Read now
Read now
B. Hunt, M. Mocarski, W. J. Valentine & J. Langer. (2017) Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. Journal of Medical Economics 20:7, pages 663-670.
Read now
Read now
Hui Shao, Suodi Zhai, Dajin Zou, Mohammed Umer Mir, Nadine K. Zawadzki, Qian Shi, Shuqian Liu & Lizheng Shi. (2017) Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current Medical Research and Opinion 33:2, pages 359-369.
Read now
Read now
Jayne Smith-Palmer, Jay P Bae, Kristina S Boye, Kirsi Norrbacka, Barnaby Hunt & William J Valentine. (2016) Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. ClinicoEconomics and Outcomes Research 8, pages 559-571.
Read now
Read now
J. Gordon, P. McEwan, U. Sabale, B. Kartman & B. H. R. Wolffenbuttel. (2016) The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. Journal of Medical Economics 19:12, pages 1167-1174.
Read now
Read now
L. H. Chuang, B. G. Verheggen, M. Charokopou, D. Gibson, S. Grandy & B. Kartman. (2016) Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Journal of Medical Economics 19:12, pages 1127-1134.
Read now
Read now
Ulrik Pedersen-Bjergaard, Peter Lommer Kristensen, Kirsten Nørgaard, Hans Perrild, Tonny Jensen, Birger Thorsteinsson, Annie Nikolajsen & Lise Tarnow. (2016) Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Current Medical Research and Opinion 32:10, pages 1719-1725.
Read now
Read now
David Bruhn, Alan A. Martin, Ruben Tavares, Barnaby Hunt & Richard F. Pollock. (2016) Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Journal of Medical Economics 19:7, pages 672-683.
Read now
Read now
Stéphane Roze, Jayne Smith-Palmer, William J. Valentine, Mark Cook, Manisha Jethwa, Simona de Portu & John C. Pickup. (2016) Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective. Journal of Medical Economics 19:3, pages 236-242.
Read now
Read now
Frank Lavernia, Pamela Kushner, Dace Trence, Donna Rice, George Dailey & Louis Kuritzky. (2015) Recognizing and minimizing hypoglycemia: The need for individualized care. Postgraduate Medicine 127:8, pages 801-807.
Read now
Read now
Jing Deng, Shuyan Gu, Hui Shao, Hengjin Dong, Dajin Zou & Lizheng Shi. (2015) Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. Journal of Medical Economics 18:11, pages 974-989.
Read now
Read now
Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu & Hengjin Dong. (2015) Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. Journal of Medical Economics 18:10, pages 808-820.
Read now
Read now
Volker Foos, Nebibe Varol, Bradley H. Curtis, Kristina S. Boye, David Grant, James L. Palmer & Phil McEwan. (2015) Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. Journal of Medical Economics 18:6, pages 420-432.
Read now
Read now
M. Evans, M. Wolden, J. Gundgaard, B. Chubb & T. Christensen. (2015) Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. Journal of Medical Economics 18:1, pages 56-68.
Read now
Read now
Daniel Viriato, Frederico Calado, Jean-Bernard Gruenberger, Siew Hwa Ong, Davide Carvalho, José Silva-Nunes, Sukhvinder Johal & Ricardo Viana. (2014) Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. Journal of Medical Economics 17:7, pages 499-507.
Read now
Read now
Bo Ahrén. (2013) Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vascular Health and Risk Management 9, pages 155-163.
Read now
Read now
Stewart B Harris, Kamlesh Khunti, Mona Landin-Olsson, Claus B Galbo-Jørgensen, Mette Bøgelund, Barrie Chubb, Jens Gundgaard & Marc Evans. (2013) Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Preference and Adherence 7, pages 925-936.
Read now
Read now
Olena Mandrik, Johan L Severens, Olena Doroshenko, Vladymir Pan’kiv, Nonna Kravchun, Maryna Vlasenko, Mykola Hulchiy, Maryna Baljuk, Yuliia Komisarenko, Eugene Martsynik, Liubov Sokolova, Olga Zalis’ka & Boris Mankovsky. (2013) Impact of hypoglycemia on daily life of type 2 diabetes patients in Ukraine. Journal of Multidisciplinary Healthcare 6, pages 249-257.
Read now
Read now
Tiago Fonseca, John Clegg, Giuseppe Caputo, Kirsi Norrbacka, Tatiana Dilla & Maria Alvarez. (2013) The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2 in Spain. Journal of Medical Economics 16:7, pages 926-938.
Read now
Read now
William D Willis, Jesús I Diago-Cabezudo, Anne Madec-Hily & Aftab Aslam. (2013) Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey. Expert Review of Pharmacoeconomics & Outcomes Research 13:1, pages 123-130.
Read now
Read now
Martin Pfohl, Peter K. Schädlich, Franz-Werner Dippel & Katharina C. Koltermann. (2012) Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. Journal of Medical Economics 15:sup2, pages 14-27.
Read now
Read now
Yevgeniy Samyshkin, Anne-Laure Guillermin, Jennie H. Best, Steven C. Brunell & Adam Lloyd. (2012) Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. Journal of Medical Economics 15:sup2, pages 6-13.
Read now
Read now
Johan Jendle, Sherry A Martin & Zvonko Milicevic. (2012) Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opinion on Investigational Drugs 21:10, pages 1463-1474.
Read now
Read now
Anne-Laure Guillermin, Adam Lloyd, Jennie H. Best, Mary Beth DeYoung, Yevgeniy Samyshkin & Julia Aledort Gaebler. (2012) Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. Journal of Medical Economics 15:4, pages 654-663.
Read now
Read now
Asger Lund & Filip K. Knop. (2012) Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Current Medical Research and Opinion 28:5, pages 731-736.
Read now
Read now
Vasil Valov, James Palmer, Marcin Czech, Alexandra Savova & Guenka Petrova. (2012) Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria. Biotechnology & Biotechnological Equipment 26:2, pages 2937-2944.
Read now
Read now
Nitil Kedia. (2011) Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes, Metabolic Syndrome and Obesity 4, pages 337-346.
Read now
Read now
Dong-Churl Suh & Mark Aagren. (2011) Cost–effectiveness of insulin detemir: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 11:6, pages 641-655.
Read now
Read now
Carrie Fidler, Torsten Elmelund Christensen & Samantha Gillard. (2011) Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs. Journal of Medical Economics 14:5, pages 646-655.
Read now
Read now
James L. Palmer, Martin S. Knudsen, Mark Aagren & Trine L. Thomsen. (2010) Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. Journal of Medical Economics 13:2, pages 212-220.
Read now
Read now
Mette Hammer, Morten Lammert, Susana Monereo Mejías, Werner Kern & Brian M. Frier. (2009) Costs of managing severe hypoglycaemia in three European countries. Journal of Medical Economics 12:4, pages 281-290.
Read now
Read now
Craig J. Currie, Chris D. Poole & Natalie L. Papo. (2009) An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes. Current Medical Research and Opinion 25:10, pages 2389-2400.
Read now
Read now
Sandra L. Tunis, Michael E. Minshall, Christopher Conner, John I. McCormick, Jovana Kapor, Jean-François Yale & Danielle Groleau. (2009) Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Current Medical Research and Opinion 25:5, pages 1273-1284.
Read now
Read now
Manuela Helena Gschwend, Mark Aagren & William J Valentine. (2009) Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. Journal of Medical Economics 12:2, pages 114-123.
Read now
Read now
James L. Palmer, Gordon Goodall, Steffen Nielsen, Robert W. Kotchie, William J. Valentine, Andrew J. Palmer & Stéphane Roze. (2008) Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Current Medical Research and Opinion 24:5, pages 1417-1428.
Read now
Read now
Henry Howard Goldstein. (2008) Pen Devices to Improve Patient Adherence With Insulin Therapy in Type 2 Diabetes. Postgraduate Medicine 120:3, pages 172-179.
Read now
Read now
Mohammed Ali, Jeremy White, Chen-Hui Lee, James L Palmer, Jayne Smith-Palmer, Walid Fakhoury & William J Valentine. (2008) Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. Journal of Medical Economics 11:4, pages 651-670.
Read now
Read now
P Banck-Petersen, T Larsen, U Pedersen-Bjergaard, L Bie-Olsen, T Høi-Hansen & B Thorsteinsson. (2007) Concerns about hypoglycaemia and late complications in patients with insulin-treated diabetes. European Diabetes Nursing 4:3, pages 113-118.
Read now
Read now
Phil McEwan, Chris D. Poole, Tony Tetlow, Paul Holmes & Craig J. Currie. (2007) Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion 23:sup1, pages S21-S31.
Read now
Read now
Phil McEwan, Chris D. Poole, Tony Tetlow, Paul Holmes & Craig J. Currie. (2007) Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Current Medical Research and Opinion 23:sup1, pages S7-S19.
Read now
Read now
Simon Dixon & John R. Peters. (2007) Evaluating the ‘real’ cost-effectiveness of health technology: reconciling the public interest with patients’ interests. Current Medical Research and Opinion 23:sup1, pages S1-S6.
Read now
Read now
Articles from other publishers (161)
Johan Jendle, Maria Ida BuompensiereAsli Zeynep Ozdemir SaltikSimona de PortuJayne Smith-Palmer, Richard F. PollockOhad Cohen. (2023) A European Cost–Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes. Diabetes Technology & Therapeutics 25:12, pages 864-876.
Crossref
Crossref
Hamza Alshannaq, Greg Cogswell, Richard F. Pollock, Waqas Ahmed, Greg J. Norman, Peter M. Lynch & Stephane Roze. (2023) Cost‐utility of real‐time continuous glucose monitoring versus self‐monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark. Diabetes, Obesity and Metabolism.
Crossref
Crossref
Marzieh Nosrati, Soroush Ahmadi Fariman, Parisa Saiyarsarai & Shekoufeh Nikfar. (2023) Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran. Journal of Diabetes & Metabolic Disorders 22:1, pages 817-825.
Crossref
Crossref
Murray D. Smith, Colin Ridyard, Vanessa Botan, Amanda Brewster, Sally Dunmore, June James, Kamlesh Khunti, Despina Laparidou, Graham Law, Pauline Mountain, Leon Roberts, Elise Rowan, Robert Spaight, Keith Spurr & Aloysius N. Siriwardena. (2023) Model-based economic evaluation of the effectiveness of “‘Hypos’ can strike twice”, a leaflet-based ambulance clinician referral intervention to prevent recurrent hypoglycaemia. PLOS ONE 18:3, pages e0282987.
Crossref
Crossref
Robert J.H. Miller, Derek S. Chew, Lei Qin, Nowell M. Fine, Jieling Chen, John J.V. McMurray, Jonathan G. Howlett & Phil McEwan. (2023) Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. European Journal of Heart Failure 25:2, pages 238-247.
Crossref
Crossref
Phil McEwan, Oliver Darlington, Ryan Miller, John J.V. McMurray, David C. Wheeler, Hiddo J.L. Heerspink, Andrew Briggs, Klas Bergenheim & Juan Jose Garcia Sanchez. (2022) Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology 17:12, pages 1730-1741.
Crossref
Crossref
Samuel J. P. Malkin, Davide Carvalho, Catarina Costa, Vasco Conde & Barnaby Hunt. (2022) The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetology & Metabolic Syndrome 14:1.
Crossref
Crossref
John J. Isitt, Stéphane Roze, Helen Sharland, Greg Cogswell, Hamza Alshannaq, Gregory J. Norman & Peter M. Lynch. (2022) Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK. Diabetes Therapy 13:11-12, pages 1875-1890.
Crossref
Crossref
Jin G. Choi, Aaron N. WinnM. Reza Skandari, Melissa I. Franco, Erin M. StaabJason Alexander, Wen WanMengqi Zhu, Elbert S. Huang, Louis Philipson & Neda Laiteerapong. (2022) First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Annals of Internal Medicine 175:10, pages 1392-1400.
Crossref
Crossref
J. J. Isitt, S. Roze, D. Tilden, N. Arora, A. J. Palmer, T. Jones, D. Rentoul & P. Lynch. (2022) Long‐term cost‐effectiveness of Dexcom G6 real‐time continuous glucose monitoring system in people with type 1 diabetes in Australia. Diabetic Medicine 39:7.
Crossref
Crossref
Sara Stafford, Peter G. Bech, Adam Fridhammar, Nino Miresashvili, Andreas Nilsson, Michael Willis & Aiden Liu. (2022) Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. Applied Health Economics and Health Policy 20:4, pages 543-555.
Crossref
Crossref
Josep Franch-Nadal, Samuel J. P. Malkin, Barnaby Hunt, Virginia Martín, María Gallego Estébanez & Josep Vidal. (2022) The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. Advances in Therapy 39:7, pages 3180-3198.
Crossref
Crossref
Vaia LambadiariAsli Zeynep Ozdemir SaltikSimona de PortuMaria Ida BuompensiereAikaterini KountouriEmmanouil KorakasHelen Sharland & Ohad Cohen. (2022) Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece. Diabetes Technology & Therapeutics 24:5, pages 316-323.
Crossref
Crossref
Fleur Levrat-Guillen & Tara Ghazi. (2022) Cost-Effectiveness of Intermittently Scanned Continuous Glucose Monitoring Versus Advanced Hybrid Closed-Loop Systems in Type 1 Diabetes: Comment on Jendle et al.. Diabetes Therapy 13:5, pages 1121-1123.
Crossref
Crossref
Erik H. Serné, Stéphane Roze, Maria I. Buompensiere, William J. Valentine, Simona De Portu & Harold W. de Valk. (2022) Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands. Advances in Therapy 39:4, pages 1844-1856.
Crossref
Crossref
Veronique Lambert-Obry, Jean-Philippe Lafrance, Michelle Savoie & Jean Lachaine. (2022) The Impact of Hypoglycemia on Productivity Loss and Utility in Patients With Type 2 Diabetes Treated With Insulin in Real-world Canadian Practice: Protocol for a Prospective Study. JMIR Research Protocols 11:3, pages e35461.
Crossref
Crossref
Robert Blissett, Deirdre Blissett, Fleur Levrat-Guillen, Harshal Deshmukh, Emma G Wilmot, Robert E J Ryder, Chris Walton & Thozhukat Sathyapalan. (2022) FreeStyle Libre Flash Glucose Monitoring system for people with type 1 diabetes in the UK: a budget impact analysis. BMJ Open Diabetes Research & Care 10:2, pages e002580.
Crossref
Crossref
Ileana Mardare, Stephen M. Campbell, Johanna C. Meyer, Israel Abebrese Sefah, Amos Massele & Brian Godman. (2022) Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care. Frontiers in Pharmacology 12.
Crossref
Crossref
Johan Jendle, M. I. Buompensiere, A. L. Holm, S. de Portu, S. J. P. Malkin & O. Cohen. (2021) The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. Diabetes Therapy 12:11, pages 2977-2991.
Crossref
Crossref
Vanessa Botan, Graham R. Law, Despina Laparidou, Elise Rowan, Murray D. Smith, Colin Ridyard, Amanda Brewster, Robert Spaight, Keith Spurr, Pauline Mountain, Sally Dunmore, June James, Leon Roberts, Kamlesh Khunti & Aloysius N. Siriwardena. (2021) The effects of a leaflet‐based intervention, ‘Hypos can strike twice’, on recurrent hypoglycaemic attendances by ambulance services: A non‐randomised stepped wedge study. Diabetic Medicine 38:10.
Crossref
Crossref
Xuanqian Xie, Jennifer Guo, Karen E Bremner, Myra Wang, Baiju R Shah & Andrei Volodin. (2021) Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes. Journal of Comparative Effectiveness Research 10:13, pages 961-974.
Crossref
Crossref
Chiu Hang Mok, Harley H.Y. Kwok, Carmen S. Ng, Gabriel M. Leung & Jianchao Quan. (2021) Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis. Value in Health 24:7, pages 1059-1067.
Crossref
Crossref
Marc Evans, Angharad R. Morgan & Stephen C. Bain. (2021) One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. Diabetes Therapy 12:6, pages 1593-1604.
Crossref
Crossref
Matthew Capehorn, Nino Hallén, James Baker-Knight, Divina Glah & Barnaby Hunt. (2021) Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Diabetes Therapy 12:2, pages 537-555.
Crossref
Crossref
Stéphane Roze, John J. Isitt, Jayne Smith-Palmer, Peter Lynch, Brigitte Klinkenbijl, Gerald Zammit & Pierre-Yves Benhamou. (2020) Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France. Diabetes Therapy 12:1, pages 235-246.
Crossref
Crossref
Ana María Castellano-Guerrero, Raquel Guerrero, Desireé Ruiz-Aranda, Sofia Perea, Alfonso Pumar, Federico Relimpio, Miguel Angel Mangas, Fernando Losada & Maria Asunción Martínez-Brocca. (2020) Gender differences in quality of life in adults with long-standing type 1 diabetes mellitus. Diabetology & Metabolic Syndrome 12:1.
Crossref
Crossref
Samer Muthana Sarsam, Hosam Al-Samarraie & Ahmed Al-Sadi. (2020) Disease discovery-based emotion lexicon: a heuristic approach to characterise sicknesses in microblogs. Network Modeling Analysis in Health Informatics and Bioinformatics 9:1.
Crossref
Crossref
Phil McEwan, Oliver Darlington, John J.V. McMurray, Pardeep S. Jhund, Kieran F. Docherty, Michael Böhm, Mark C. Petrie, Klas Bergenheim & Lei Qin. (2020)
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of
DAPA‐HF
. European Journal of Heart Failure 22:11, pages 2147-2156.
Crossref
Crossref
Stéphane Roze, John Isitt, Jayne Smith-Palmer, Mehdi JavanbakhtPeter Lynch. (2020) Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.. Diabetes Care 43:10, pages 2411-2417.
Crossref
Crossref
Virginia Martín, Josep Vidal, Samuel J. P. Malkin, Nino Hallén & Barnaby Hunt. (2020) Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Advances in Therapy 37:10, pages 4427-4445.
Crossref
Crossref
Jingwen Liu, Jeoffrey Bispham, Ludi Fan, Jiat-Ling Poon, Allyson Hughes, Alicia Mcauliffe-Fogarty, Oralee Varnado & Beth Mitchell. (2020) Factors associated with fear of hypoglycaemia among the T1D Exchange Glu population in a cross-sectional online survey. BMJ Open 10:9, pages e038462.
Crossref
Crossref
Hayley Bennett, Amarjeet Tank, Marc Evans, Klas Bergenheim & Phil McEwan. (2020) Cost‐effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes, Obesity and Metabolism 22:7, pages 1047-1055.
Crossref
Crossref
Margarita Capel, Andreea Ciudin, María Mareque, Raquel María Rodríguez-Rincón, Susana Simón & Itziar Oyagüez. (2019) Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus. PharmacoEconomics - Open 4:2, pages 277-286.
Crossref
Crossref
Jason Gordon, Lee Beresford‐Hulme, Hayley Bennett, Amarjeet Tank, Christopher Edmonds & Phil McEwan. (2020) Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme. Diabetes, Obesity and Metabolism 22:5, pages 857-865.
Crossref
Crossref
Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J. P. Malkin, Anna Sandberg & Matthew Capehorn. (2020) Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Advances in Therapy 37:5, pages 2427-2441.
Crossref
Crossref
Marc Evans, Robert G. J. Moes, Katrine S. Pedersen, Jens Gundgaard & Thomas R. Pieber. (2020) Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial. Advances in Therapy 37:5, pages 2413-2426.
Crossref
Crossref
Pierre Johansen, Anna Sandberg & Matthew Capehorn. (2020) A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Advances in Therapy 37:3, pages 1248-1259.
Crossref
Crossref
Kelsey Maass & Minsun Kim. (2020) A Markov decision process approach to optimizing cancer therapy using multiple modalities. Mathematical Medicine and Biology: A Journal of the IMA 37:1, pages 22-39.
Crossref
Crossref
Stephen C. Bain, Brian B. Hansen, Samuel J. P. Malkin, Solomon Nuhoho, William J. Valentine, Barrie Chubb, Barnaby Hunt & Matthew Capehorn. (2019) Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Diabetes Therapy 11:1, pages 259-277.
Crossref
Crossref
Pamela Martyn-Nemeth, Jennifer Duffecy, Laurie Quinn, Chang Park, Dan Mihailescu & Sue Penckofer. (2019) A cognitive behavioral therapy intervention to reduce fear of hypoglycemia in young adults with type 1 diabetes (FREE): study protocol for a randomized controlled trial. Trials 20:1.
Crossref
Crossref
Stéphane RozeJayne Smith-PalmerSimona de PortuA. Zeynep Özdemir SaltikTuğba AkgülOğuzhan Deyneli. (2019) Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. Diabetes Technology & Therapeutics 21:12, pages 727-735.
Crossref
Crossref
Richard F. Pollock, William J. Valentine, Steven P. Marso, Andreas Andersen, Jens Gundgaard, Nino Hallén, Deniz Tutkunkardas, Elizabeth A. Magnuson & John B. Buse. (2019) Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied Health Economics and Health Policy 17:5, pages 615-627.
Crossref
Crossref
Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt & Samuel Joseph Paul Malkin. (2019) Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Therapy 10:4, pages 1297-1317.
Crossref
Crossref
Samuel J. P. Malkin, Monika Russel-Szymczyk, Marek Psota, Lucia Hlavinkova & Barnaby Hunt. (2019) The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Advances in Therapy 36:8, pages 2034-2051.
Crossref
Crossref
Richard F. Pollock, Simon Heller, Thomas R. Pieber, Vincent Woo, Jens Gundgaard, Nino Hallén, Maria Luckevich, Deniz Tutkunkardas & Bernard Zinman. (2019) Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, Obesity and Metabolism 21:7, pages 1706-1714.
Crossref
Crossref
Johannes Pöhlmann, Monika Russel-Szymczyk, Pavel Holík, Karel Rychna & Barnaby Hunt. (2019) Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi. Diabetes Therapy 10:2, pages 493-508.
Crossref
Crossref
Adie Viljoen, Christina S. Hoxer, Pierre Johansen, Samuel Malkin, Barnaby Hunt & Stephen C. Bain. (2019) Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism 21:3, pages 611-621.
Crossref
Crossref
Johan JendleJohannes PöhlmannSimona de PortuJayne Smith-PalmerStéphane Roze. (2019) Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. Diabetes Technology & Therapeutics 21:3, pages 110-118.
Crossref
Crossref
Mitsuyoshi Takahara, Naoto Katakami, Toshihiko Shiraiwa, Katsushige Abe, Hideo Ayame, Yasuaki Ishimaru, Masahiro Iwamoto, Mitsuo Shimizu, Osamu Tomonaga, Hiroki Yokoyama, Taka-aki Matsuoka & Iichiro Shimomura. (2018) Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L. Acta Diabetologica 56:3, pages 309-319.
Crossref
Crossref
Samuel J. P. Malkin, Monika Russel-Szymczyk, Girtel Liidemann, Vallo Volke & Barnaby Hunt. (2018) Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes Therapy 10:1, pages 159-176.
Crossref
Crossref
P. C. Lee, S. Ganguly & S.-Y. Goh. (2018) Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obesity Reviews 19:12, pages 1630-1641.
Crossref
Crossref
Russell Drummond, Samuel Malkin, Michelle Du Preez, Xin Ying Lee & Barnaby Hunt. (2018) The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, Obesity and Metabolism 20:10, pages 2371-2378.
Crossref
Crossref
Ignacio Conget, Pilar Martín-Vaquero, Stéphane Roze, Isabel Elías, Cristina Pineda, María Álvarez, Alexis Delbaere & Francisco Javier Ampudia-Blasco. (2018) Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. Endocrinología, Diabetes y Nutrición 65:7, pages 380-386.
Crossref
Crossref
Ignacio Conget, Pilar Martín-Vaquero, Stéphane Roze, Isabel Elías, Cristina Pineda, María Álvarez, Alexis Delbaere & Francisco Javier Ampudia-Blasco. (2018) Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. Endocrinología, Diabetes y Nutrición (English ed.) 65:7, pages 380-386.
Crossref
Crossref
A. Nicolucci, M.C. Rossi, D. D'Ostilio, A. Delbaere, S. de Portu & S. Roze. (2018) Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. Nutrition, Metabolism and Cardiovascular Diseases 28:7, pages 707-715.
Crossref
Crossref
Richard F. Pollock, William J. Valentine, Steven P. Marso, Jens Gundgaard, Nino Hallén, Lars L. Hansen, Deniz Tutkunkardas & John B. Buse. (2018) DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK. Diabetes Therapy 9:3, pages 1217-1232.
Crossref
Crossref
P. McEwan, H. Bennett, K. Bolin, M. Evans & K. Bergenheim. (2018)
Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA
1c
, weight and hypoglycaemic event incidence
. Diabetic Medicine 35:5, pages 557-566.
Crossref
Crossref
Clara Tasende, José Antonio Rubio & Julia Álvarez. (2018) Traducción al español, adaptación y validación del Cuestionario de miedo a la hipoglucemia en adultos con diabetes tipo 1 de la Comunidad de Madrid. Endocrinología, Diabetes y Nutrición 65:5, pages 287-296.
Crossref
Crossref
Clara Tasende, José Antonio Rubio & Julia Álvarez. (2018) Spanish translation, adaptation and validation of the Hypoglycemia Fear Survey in adults with type 1 diabetes in the Community of Madrid. Endocrinología, Diabetes y Nutrición (English ed.) 65:5, pages 287-296.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Michael Willis, Pierre Johansen & Lien Vo. (2018) Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy 9:2, pages 565-581.
Crossref
Crossref
S Pinar Bilir, Richard Hellmund, Elizabeth Wehler, Huimin Li, Julie Munakata & Mark Lamotte. (2018) The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden. European Endocrinology 14:2, pages 80.
Crossref
Crossref
S Pinar Bilir, Richard Hellmund, Beth Wehler, Huimin Li, Julie Munakata & Mark Lamotte. (2018) Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden. European Endocrinology 14:2, pages 73.
Crossref
Crossref
Asrul A. Shafie & Chin H. Ng. 2018. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries
129
142
.
Hara Kousoulakou, Magdalini Hatzikou, Varvara Baroutsou & John Yfantopoulos. (2017) Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece. Cost Effectiveness and Resource Allocation 15:1.
Crossref
Crossref
Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang & Hengjin Dong. (2017) Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. Diabetes, Obesity and Metabolism 19:12, pages 1688-1697.
Crossref
Crossref
Dalia Dawoud, Elisabetta Fenu, Bernard Higgins, David Wonderling & Stephanie A. Amiel. (2017) Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis. Value in Health 20:10, pages 1279-1287.
Crossref
Crossref
Milan Kvapil, Martin Prázný, Pavel Holik, Karel Rychna & Barnaby Hunt. (2017) Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic. Diabetes Therapy 8:6, pages 1331-1347.
Crossref
Crossref
Johan Jendle, Jayne Smith-Palmer, Alexis Delbaere, Simona de Portu, Natalie Papo, William Valentine & Stéphane Roze. (2017) Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden. Diabetes Therapy 8:5, pages 1015-1030.
Crossref
Crossref
Jay P. Bae, Ran Duan, Haoda Fu & Byron J. Hoogwerf. (2017) Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database. Clinical Therapeutics 39:9, pages 1790-1798.e7.
Crossref
Crossref
Barnaby Hunt, Nana Kragh, Ceilidh C. McConnachie, William J. Valentine, Maria C. Rossi & Roberta Montagnoli. (2017) Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. Clinical Therapeutics 39:7, pages 1347-1359.
Crossref
Crossref
Barnaby Hunt, Gabriela Vega-Hernandez, William J. Valentine & Nana Kragh. (2017) Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes, Obesity and Metabolism 19:6, pages 842-849.
Crossref
Crossref
S. Roze, S. de Portu, J. Smith-Palmer, A. Delbaere, W. Valentine & M. Ridderstråle. (2017) Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark. Diabetes Research and Clinical Practice 128, pages 6-14.
Crossref
Crossref
Barnaby Hunt, Michelle Mocarski, William J. Valentine & Jakob Langer. (2017) IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Therapy 8:3, pages 531-544.
Crossref
Crossref
Pedro Mezquita-Raya, Antonio Ramírez de Arellano, Nana Kragh, Gabriela Vega-Hernandez, Johannes Pöhlmann, William J. Valentine & Barnaby Hunt. (2017) Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Therapy 8:2, pages 401-415.
Crossref
Crossref
Marc Evans, Barrie Chubb & Jens Gundgaard. (2017) Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. Diabetes Therapy 8:2, pages 275-291.
Crossref
Crossref
Frédéric Lapostolle, Nadia Hamdi, Majed Barghout, Louis Soulat, Anna Faucher, Yves Lambert, Nicolas Peschanski, Agnès Ricard-Hibon, Carine Chassery, Maryline Roti, Vincent Bounes, Guillaume Debaty, Tarak Mokni, Gérald Egmann, Pierre-Arnaud Fort, Karim Boudenia, Laurent Alayrac, Mohamed Safraou, Michel Galinski & Frédéric Adnet. (2016) Diabetes education of patients and their entourage: out-of-hospital national study (EDUCATED 2). Acta Diabetologica 54:4, pages 353-360.
Crossref
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Crossref
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt & Norman Waugh. (2017) Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment 21:2, pages 1-218.
Crossref
Crossref
Obinna Ikechukwu Ekwunife, Charles C. Ezenduka & Bede Emeka Uzoma. (2016) Evaluating the sensitivity of EQ-5D in a sample of patients with type 2 diabetes mellitus in two tertiary health care facilities in Nigeria. BMC Research Notes 9:1.
Crossref
Crossref
Marc Evans, Jens Gundgaard & Brian Bekker Hansen. (2016) Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective. Diabetes Therapy 7:4, pages 809-823.
Crossref
Crossref
Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu & Hengjin Dong. (2016) Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLOS ONE 11:11, pages e0167190.
Crossref
Crossref
Shuyan Gu, Yiming Mu, Suodi Zhai, Yuhang Zeng, Xuemei Zhen & Hengjin Dong. (2016) Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLOS ONE 11:11, pages e0165629.
Crossref
Crossref
Tessa Peasgood, Alan Brennan, Peter Mansell, Jackie Elliott, Hasan Basarir & Jen Kruger. (2016) The Impact of Diabetes-Related Complications on Preference-Based Measures of Health-Related Quality of Life in Adults with Type I Diabetes. Medical Decision Making 36:8, pages 1020-1033.
Crossref
Crossref
Ana Maria Gomez, Rafael Alfonso-Cristancho, John Jairo Orozco, Peter Matthew Lynch, Diana Prieto, Rhodri. Saunders, Stephane Roze & Juan Esteban Valencia. (2016) Beneficios cl?nicos y econ?micos de la terapia con bomba de insulina integrada a sistema de monitoreo continuo de glucosa en los pacientes diab?ticos tipo 1 en Colombia. Endocrinolog?a y Nutrici?n 63:9, pages 466-474.
Crossref
Crossref
Ana Maria Gomez, Rafael Alfonso-Cristancho, John Jairo Orozco, Peter Matthew Lynch, Diana Prieto, Rhodri Saunders, Stephane Roze & Juan Esteban Valencia. (2016) Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia. Endocrinología y Nutrición (English Edition) 63:9, pages 466-474.
Crossref
Crossref
Phil McEwan, Hayley Bennett, Jonathan Fellows, Jennifer Priaulx & Klas Bergenheim. (2016) The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. PLOS ONE 11:9, pages e0162441.
Crossref
Crossref
Rob Riemsma, Isaac Corro Ramos, Richard Birnie, Nasuh Büyükkaramikli, Nigel Armstrong, Steve Ryder, Steven Duffy, Gill Worthy, Maiwenn Al, Johan Severens & Jos Kleijnen. (2016) Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technology Assessment 20:17, pages 1-252.
Crossref
Crossref
Stéphane RozeJayne Smith-PalmerWilliam ValentineVincent PayetSimona de PortuNatalie PapoMichel CucheratHelene Hanaire. (2016) Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France. Diabetes Technology & Therapeutics 18:2, pages 75-84.
Crossref
Crossref
Joaquín Sánchez-Covisa, Josep Franch, Dídac Mauricio, Noemí López-Martínez, Ling-Hsiang Chuang & Margarita Capel. (2015) Análisis de coste-efectividad de saxagliptina como tratamiento triple oral (con metformina y una sulfonilurea) en el manejo de la diabetes tipo 2 en España. PharmacoEconomics Spanish Research Articles 13:1, pages 25-35.
Crossref
Crossref
Pamela Martyn-Nemeth, Sarah Schwarz Farabi, Dan Mihailescu, Jeffrey Nemeth & Laurie Quinn. (2016) Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention - a review. Journal of Diabetes and its Complications 30:1, pages 167-177.
Crossref
Crossref
Barnaby Hunt, José Luis Aguilar Garza, Carlos Jesús Enríquez Vázquez, Pavika Jain & William J. Valentine. (2015) Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. Value in Health Regional Issues 8, pages 20-27.
Crossref
Crossref
Lyudmila Alexandrovna Suplotova, Nikolay Valer'evich Plotnikov, Natal'ya Valer'yanovna Romanova, Larisa Nikolaevna Bel’chikova, Ekaterina Viktorovna Khieva & Marina Vladimirovna Shestakova. (2015) Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice. Diabetes mellitus 18:4, pages 92-98.
Crossref
Crossref
Eduardo José Abad Paniagua, Pedro Casado Escribano, José María Fernández Rodriguez, Francisco J. Morales Escobar, Lourdes Betegón Nicolás, Joaquín Sánchez-Covisa & Max Brosa. (2015) Análisis de coste-efectividad de dapagliflozina en comparación con los inhibidores de la DPP4 y otros antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2 en España. Atención Primaria 47:8, pages 505-513.
Crossref
Crossref
Phil McEwanJason GordonMarc EvansThomas WardHayley BennettKlas Bergenheim. (2015) Estimating Cost-Effectiveness in Type 2 Diabetes. Medical Decision Making 35:5, pages 660-670.
Crossref
Crossref
M. Charokopou, P. McEwan, S. Lister, L. Callan, K. Bergenheim, K. Tolley, R. Postema, R. Townsend & M. Roudaut. (2015) The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Medicine 32:7, pages 890-898.
Crossref
Crossref
M. Charokopou, P. McEwan, S. Lister, L. Callan, K. Bergenheim, K. Tolley, R. Postema, R. Townsend & M. Roudaut. (2015) Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. BMC Health Services Research 15:1.
Crossref
Crossref
S. Roze, R. Saunders, A.-S. Brandt, S. de Portu, N. L. Papo & J. Jendle. (2015) Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes. Diabetic Medicine 32:5, pages 618-626.
Crossref
Crossref
K. Dżygało, D. Golicki, A. Kowalska & A. Szypowska. (2014) The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials. Acta Diabetologica 52:2, pages 231-238.
Crossref
Crossref
Ugne Sabale, Mattias Ekman, Ola Granström, Klas Bergenheim & Phil McEwan. (2015) Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes 9:1, pages 39-47.
Crossref
Crossref
Gregory D. Stevens, Leiyu Shi, Christina Vane, Xiaoyu Nie & Anne L. Peters. (2014) Primary Care Medical Home Experience and Health-Related Quality of Life Among Adult Medicaid Patients with Type 2 Diabetes. Journal of General Internal Medicine 30:2, pages 161-168.
Crossref
Crossref
Stephen T. Brown, Daniel Grima Grima & Luc Sauriol. (2014) Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics 36:11, pages 1576-1587.
Crossref
Crossref
Jørgen T. Lauridsen, Jonas Lønborg, Jens Gundgaard & Henrik Holm Jensen. (2014) Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Quality of Life Research 23:9, pages 2645-2650.
Crossref
Crossref
Lill-Brith von Arx & Trine Kjær. (2014) The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research. The Patient - Patient-Centered Outcomes Research 7:3, pages 283-300.
Crossref
Crossref
Trang T. Ly, Alan J.M. Brnabic, Andrew Eggleston, Athena Kolivos, Margaret E. McBride, Rudolf Schrover & Timothy W. Jones. (2014) A Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension versus Standard Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes. Value in Health 17:5, pages 561-569.
Crossref
Crossref
Amélie Beaudet, John Clegg, Per-Olof Thuresson, Adam Lloyd & Phil McEwan. (2014) Review of Utility Values for Economic Modeling in Type 2 Diabetes. Value in Health 17:4, pages 462-470.
Crossref
Crossref
S. Goring, N. Hawkins, G. Wygant, M. Roudaut, R. Townsend, I. Wood & A. H. Barnett. (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism 16:5, pages 433-442.
Crossref
Crossref
Caroline Whately-Smith, Claire Watkins, Helen Mann, Chrissie Fletcher & Pierre Ducournau. (2014) Utility values in health technology assessments: a statistician's perspective. Pharmaceutical Statistics 13:3, pages 184-195.
Crossref
Crossref
P. D. Home. (2014) The vexed question of hypoglycaemia and health economics. Diabetes, Obesity and Metabolism 16:4, pages 289-293.
Crossref
Crossref
M. Evans, M. Wolden, J. Gundgaard, B. Chubb & T. Christensen. (2014) Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Diabetes, Obesity and Metabolism 16:4, pages 366-375.
Crossref
Crossref
W. Polonsky, L. Traylor, W. Wei, R. Shi, B. Ameer, A. Vlajnic & A. Nicolucci. (2014) More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 16:3, pages 255-261.
Crossref
Crossref
Manuel Mu?oz Torres. (2014) Degludec, una nueva insulina basal de acci?n ultra-lenta para el tratamiento de la diabetes tipo 1 y 2: avances en investigaci?n cl?nica. Endocrinolog?a y Nutrici?n 61:3, pages 153-159.
Crossref
Crossref
Manuel Mu?oz Torres. (2014) Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: Advances in clinical research. Endocrinolog?a y Nutrici?n (English Edition) 61:3, pages 153-159.
Crossref
Crossref
Stewart Harris, Muhammad Mamdani, Claus B. Galbo-Jørgensen, Mette Bøgelund, Jens Gundgaard & Danielle Groleau. (2014) The Effect of Hypoglycemia on Health-Related Quality of Life: Canadian Results from a Multinational Time Trade-off Survey. Canadian Journal of Diabetes 38:1, pages 45-52.
Crossref
Crossref
Heleen G. M. van Haalen, Marjolein Pompen, Klas Bergenheim, Phil McEwan, Rebecca Townsend & Marina Roudaut. (2013) Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type?2 Diabetes Mellitus in the Netherlands. Clinical Drug Investigation 34:2, pages 135-146.
Crossref
Crossref
Nicola N. Zammitt & Brian M. Frier. 2014. Hypoglycaemia in Clinical Diabetes. Hypoglycaemia in Clinical Diabetes
230
262
.
M. Te?fila Vicente-Herrero, M. Jes?s Terradillos Garc?a, Luisa M. Capdevila Garc?a, M. Victoria Ram?rez I?iguez de la Torre & ?ngel Arturo L?pez-Gonz?lez. (2013) Costes por incapacidad temporal en Espa?a derivados de la diabetes mellitus y sus complicaciones. Endocrinolog?a y Nutrici?n 60:8, pages 447-455.
Crossref
Crossref
M. Te?fila Vicente-Herrero, M. Jes?s Terradillos Garc?a, Luisa M. Capdevila Garc?a, M. Victoria Ram?rez I?iguez de la Torre & ?ngel Arturo L?pez-Gonz?lez. (2013) Costs of temporary disability in Spain related to diabetes mellitus and its complications. Endocrinolog?a y Nutrici?n (English Edition) 60:8, pages 447-455.
Crossref
Crossref
Ilhan Satman, Hayley Bennett, Candeger Yilmaz, Sazi Imamoglu, Goksun Ayvaz, Abdurrahman Comlekci, Demet Ozkaya & Toros Sahin. (2013) Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey. Journal of Health Economics and Outcomes Research 1:2, pages 108-122.
Crossref
Crossref
N. Freemantle, M. Evans, T. Christensen, M. L. Wolden & J. B. Bjorner. (2013) A comparison of health‐related quality of life (health utility) between insulin degludec and insulin glargine: a meta‐analysis of phase 3 trials. Diabetes, Obesity and Metabolism 15:6, pages 564-571.
Crossref
Crossref
Marc Evans, Kamlesh Khunti, Muhammad Mamdani, Claus B Galbo-Jørgensen, Jens Gundgaard, Mette Bøgelund & Stewart Harris. (2013) Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health and Quality of Life Outcomes 11:1, pages 90.
Crossref
Crossref
G. Luippold, T. Klein, M. Mark & R. Grempler. (2012) Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes, Obesity and Metabolism 14:7, pages 601-607.
Crossref
Crossref
Ola Granström, Klas Bergenheim, Phil McEwan, Karin Sennfält & Martin Henriksson. (2012) Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Primary Care Diabetes 6:2, pages 127-136.
Crossref
Crossref
Shital Kamble, Kevin A. Schulman & Shelby D. Reed. (2012) Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States. Value in Health 15:5, pages 632-638.
Crossref
Crossref
P. D. Home, L. Meneghini, U. Wendisch, R. E. Ratner, T. Johansen, T. E. Christensen, J. Jendle, A. P. Roberts & K. I. Birkeland. (2012) Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. Diabetic Medicine 29:6, pages 716-720.
Crossref
Crossref
Marcelo Eidi Nita, Freddy G. Eliaschewitz, Eliane Ribeiro, Elio Asano, Elias Barbosa, Maíra Takemoto, Bonnie Donato, Roberto Rached & Elaine Rahal. (2012) Custo-efetividade e impacto orçamentário da saxagliptina como terapia adicional à metformina para o tratamento do diabetes mellitus tipo 2 no sistema de saúde suplementar do Brasil. Revista da Associação Médica Brasileira 58:3, pages 294-301.
Crossref
Crossref
Marcelo Eidi Nita, Freddy G. Eliaschewitz, Eliane Ribeiro, Elio Asano, Elias Barbosa, Maíra Takemoto, Bonnie Donato, Roberto Rached & Elaine Rahal. (2012) Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. Revista da Associação Médica Brasileira (English Edition) 58:3, pages 294-301.
Crossref
Crossref
Marcelo Eidi Nita, Freddy G. Eliaschewitz, Eliane Ribeiro, Elio Asano, Elias Barbosa, Maíra Takemoto, Bonnie Donato, Roberto Rached & Elaine Rahal. (2012) Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. Revista da Associação Médica Brasileira 58:3, pages 294-301.
Crossref
Crossref
Wilma Erhardt, Klas Bergenheim, Isabelle Duprat-Lomon & Phil McEwan. (2012) Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. Clinical Drug Investigation 32:3, pages 189-202.
Crossref
Crossref
W. J. Valentine, J. Jendle, M. Saraheimo, B. Thorsteinsson, R. F. Pollock & M. Lammert. (2012) Evaluating the cost‐effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabetic Medicine 29:3, pages 303-312.
Crossref
Crossref
Wladyslaw GrzeszczakLeszek CzupryniakKatarzyna KolasaCezary SciborskiIsabelle Duprat LomonPhil McEwan. (2012) The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland. Diabetes Technology & Therapeutics 14:1, pages 65-73.
Crossref
Crossref
Li Yang, Torsten Christensen, Fengyu Sun & Jinghua Chang. (2012) Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study. Value in Health 15:1, pages S56-S59.
Crossref
Crossref
Elizabeth Marrett, Larry Radican, Michael J Davies & Qiaoyi Zhang. (2011) Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Research Notes 4:1.
Crossref
Crossref
Siddharth Shah, Alexey Zilov, Rachid Malek, Pradana Soewondo, Ole Bech & Leon Litwak. (2011) Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study. Diabetes Research and Clinical Practice 94:3, pages 364-370.
Crossref
Crossref
Tom W. C. Lung, Alison J. Hayes, Andrew Hayen, Andrew Farmer & Philip M. Clarke. (2011) A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Quality of Life Research 20:10, pages 1669-1678.
Crossref
Crossref
Meryl Brod, Torsten Christensen, Trine L. Thomsen & Donald M. Bushnell. (2011) The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management. Value in Health 14:5, pages 665-671.
Crossref
Crossref
Sylvie Dejager & Anja Schweizer. (2011) Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Therapy 2:2, pages 51-66.
Crossref
Crossref
William J. Valentine, Mark Aagren, Mattias Haglund, Åsa Ericsson & Manuela H. Gschwend. (2010) Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scandinavian Journal of Public Health 39:1, pages 79-87.
Crossref
Crossref
Ernst-Günther Hagenmeyer, Katharina C Koltermann, Franz-Werner Dippel & Peter K Schädlich. (2011) Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review. Cost Effectiveness and Resource Allocation 9:1, pages 15.
Crossref
Crossref
Christopher Ll. Morgan, Marc Evans, Anders D. Toft, Sara Jenkins-Jones, Chris D. Poole & Craig J. Currie. (2011) Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study. Clinical Therapeutics 33:1, pages 27-35.
Crossref
Crossref
H. Mosnier-Pudar, G. Hochberg, E. Eschwege, S. Halimi, M.-L. Virally, P.-J. Guillausseau, C. Touboul & S. Dejager. (2010) How patients’ attitudes and opinions influence self-care behaviours in type 2 diabetes. Insights from the French DIABASIS Survey. Diabetes & Metabolism 36:6, pages 476-483.
Crossref
Crossref
James L. Palmer, Amélie Beaudet, Jeremy White, Juliette Plun-Favreau & Jayne Smith-Palmer. (2010) Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Advances in Therapy 27:11, pages 814-827.
Crossref
Crossref
T. Anderbro, S. Amsberg, U. Adamson, J. Bolinder, P.‐E. Lins, R. Wredling, E. Moberg, J. Lisspers & U.‐B. Johansson. (2010) Fear of hypoglycaemia in adults with Type 1 diabetes. Diabetic Medicine 27:10, pages 1151-1158.
Crossref
Crossref
Sandra L. Tunis, Luc Sauriol & Michael E. Minshall. (2010) Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada. Applied Health Economics and Health Policy 8:4, pages 267-280.
Crossref
Crossref
Displaying 200 of 218 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list